FDA approves Schwarz Pharma, Pfiser Bladder Drug
A drug designed to treat patients with overactive bladders was granted FDA approval today.
Toviaz, generically known as fesoterodine fumarate, manufactured by Schwarz Pharma and distributed by Pfiser Inc., works by relaxing smooth muscle tissue in the bladder to decrease urinary leaks and frequency of urination, according to a statement released by the FDA.
It is approved for adults, except for those with severely decreased liver function and narrow-angle glaucoma which is not under control.
Side-effects of the drug include constipation and dry mouth, or in less common instances, dry eyes and trouble emptying the bladder.